256 related articles for article (PubMed ID: 27865174)
1. Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up.
Ripa M; Pogliaghi M; Chiappetta S; Nozza S; Soria A; Coppalini G; Rovelli C; Tambussi G
J Clin Virol; 2016 Dec; 85():86-89. PubMed ID: 27865174
[TBL] [Abstract][Full Text] [Related]
2. Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial.
van Lelyveld SF; Drylewicz J; Krikke M; Veel EM; Otto SA; Richter C; Soetekouw R; Prins JM; Brinkman K; Mulder JW; Kroon F; Middel A; Symons J; Wensing AM; Nijhuis M; Borghans JA; Tesselaar K; Hoepelman AI;
PLoS One; 2015; 10(7):e0132430. PubMed ID: 26208341
[TBL] [Abstract][Full Text] [Related]
3. Addition of maraviroc to antiretroviral therapy decreased interferon-γ mRNA in the CD4+ T cells of patients with suboptimal CD4+ T-cell recovery.
Minami R; Takahama S; Kaku Y; Yamamoto M
J Infect Chemother; 2017 Jan; 23(1):29-34. PubMed ID: 27729193
[TBL] [Abstract][Full Text] [Related]
4. Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study.
Nozza S; Galli L; Antinori A; Chiappetta S; Mazzotta F; Zaccarelli M; Ottou S; De Battista D; Pogliaghi M; Di Pietro M; Malnati M; Ripa M; Bonora S; Lazzarin A;
Clin Microbiol Infect; 2015 May; 21(5):510.e1-9. PubMed ID: 25656621
[TBL] [Abstract][Full Text] [Related]
5. Effect of maraviroc on HIV disease progression-related biomarkers.
Romero-Sánchez MC; Machmach K; Gonzalez-Serna A; Genebat M; Pulido I; García-García M; Alvarez-Ríos AI; Ferrando-Martinez S; Ruiz-Mateos E; Leal M
Antimicrob Agents Chemother; 2012 Nov; 56(11):5858-64. PubMed ID: 22948867
[TBL] [Abstract][Full Text] [Related]
6. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
Puertas MC; Massanella M; Llibre JM; Ballestero M; Buzon MJ; Ouchi D; Esteve A; Boix J; Manzardo C; Miró JM; Gatell JM; Clotet B; Blanco J; Martinez-Picado J;
AIDS; 2014 Jan; 28(3):325-34. PubMed ID: 24185044
[TBL] [Abstract][Full Text] [Related]
7. Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.
Mills A; Mildvan D; Podzamczer D; Fätkenheuer G; Leal M; Than S; Valluri SR; Craig C; McFadyen L; Vourvahis M; Heera J; Valdez H; Rinehart AR; Portsmouth S
J Acquir Immune Defic Syndr; 2013 Feb; 62(2):164-70. PubMed ID: 23187936
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of maraviroc addition to a stable antiretroviral regimen in subjects with suppressed plasma HIV-RNA is not influenced by age.
Blanco JR; Arroyo-Manzano D; Rojas-Liévano JF; Crespo M; Bravo I; Pasquau J; Garcia Del Toro M; Herrero C; Rivero A; Moreno S; Llibre JM
AIDS Res Hum Retroviruses; 2015 Sep; 31(9):893-7. PubMed ID: 26059859
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients.
Bocket L; Peytavin G; Alidjinou EK; Ajana F; Choisy P; Lê M; Charpentier C; Descamps D; Yazdanpanah Y; Katlama C; Simon A; Calvez V; Marcelin AG; Soulie C
J Antimicrob Chemother; 2016 Sep; 71(9):2651-3. PubMed ID: 27234463
[TBL] [Abstract][Full Text] [Related]
10. Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study.
Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Madero JS; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Alberto Arnaiz J; Cooper D; Rockstroh JK; Mallon P; Emery S;
HIV Med; 2018 Jan; 19(1):65-71. PubMed ID: 28703491
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled clinical trial on the impact of CCR5 blockade with maraviroc in early infection on T-cell dynamics.
Karris MY; Umlauf A; Vaida F; Richman D; Little S; Smith D
Medicine (Baltimore); 2016 Nov; 95(44):e5315. PubMed ID: 27858912
[TBL] [Abstract][Full Text] [Related]
12. Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc.
Chaillon A; Gianella S; Lada SM; Perez-Santiago J; Jordan P; Ignacio C; Karris M; Richman DD; Mehta SR; Little SJ; Wertheim JO; Smith DM
J Virol; 2018 Feb; 92(3):. PubMed ID: 29142136
[TBL] [Abstract][Full Text] [Related]
13. The maraviroc expanded access program - safety and efficacy data from an open-label study.
Lazzarin A; Reynes J; Molina JM; Valluri S; Mukwaya G; Heera J; Craig C; van der Ryst E; Sierra-Madero JG
HIV Clin Trials; 2015; 16(1):10-21. PubMed ID: 25777185
[TBL] [Abstract][Full Text] [Related]
14. A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256.
Wilkin TJ; Lalama CM; McKinnon J; Gandhi RT; Lin N; Landay A; Ribaudo H; Fox L; Currier JS; Mellors JW; Gulick R; Tenorio AR
J Infect Dis; 2012 Aug; 206(4):534-42. PubMed ID: 22740718
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness, safety, durability and immune recovery in a retrospective, multicentre, observational cohort of ART-experienced, HIV-1-infected patients receiving maraviroc.
Dentone C; Sterrantino G; Signori A; Cenderello G; Guerra M; De Leo P; Bartolacci V; Mantia E; Orofino G; Giacomini M; Bruzzone B; Francisci D; Di Biagio A;
Int J STD AIDS; 2017 Oct; 28(11):1067-1073. PubMed ID: 28142395
[TBL] [Abstract][Full Text] [Related]
16. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
Cillo AR; Hilldorfer BB; Lalama CM; McKinnon JE; Coombs RW; Tenorio AR; Fox L; Gandhi RT; Ribaudo H; Currier JS; Gulick RM; Wilkin TJ; Mellors JW
AIDS; 2015 Oct; 29(16):2121-9. PubMed ID: 26544577
[TBL] [Abstract][Full Text] [Related]
17. Maraviroc for previously treated patients with R5 HIV-1 infection.
Gulick RM; Lalezari J; Goodrich J; Clumeck N; DeJesus E; Horban A; Nadler J; Clotet B; Karlsson A; Wohlfeiler M; Montana JB; McHale M; Sullivan J; Ridgway C; Felstead S; Dunne MW; van der Ryst E; Mayer H;
N Engl J Med; 2008 Oct; 359(14):1429-41. PubMed ID: 18832244
[TBL] [Abstract][Full Text] [Related]
18. Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response.
Soulie C; Peytavin G; Charpentier C; Lambert-Niclot S; Sayon S; Visseaux B; Simon A; Katlama C; Yazdanpanah Y; Descamps D; Calvez V; Marcelin AG
AIDS Res Hum Retroviruses; 2015 May; 31(5):475-8. PubMed ID: 25420695
[TBL] [Abstract][Full Text] [Related]
19. A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals.
Markowitz M; Evering TH; Garmon D; Caskey M; La Mar M; Rodriguez K; Sahi V; Palmer S; Prada N; Mohri H
J Acquir Immune Defic Syndr; 2014 Jun; 66(2):140-7. PubMed ID: 24457632
[TBL] [Abstract][Full Text] [Related]
20. Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study.
Cuzin L; Trabelsi S; Delobel P; Barbuat C; Reynes J; Allavena C; Peytavin G; Ghosn J; Lascoux-Combe C; Psomas C; Corbeau P; Flandre P;
J Acquir Immune Defic Syndr; 2012 Dec; 61(5):557-64. PubMed ID: 22986949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
